Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 157 The United Laboratories International Holdings Limited Annual Report 2022 45. INFORMATION ABOUT THE STATEMENT OF FINANCIAL POSITION OF THE COMPANY (Continued) (b) Reserves Share premium Treasury stock Retained profits Total RMB’000 RMB’000 RMB’000 RMB’000 At 1 January 2021 3,805,695 – 845,226 4,650,921 Loss and total comprehensive expense for the year – – (308,830) (308,830) Dividends recognised as distribution (Note 15) – – (220,847) (220,847) Repurchase and cancellation of shares (23,267) (17,653) – (40,920) Transaction costs attributable to repurchase and cancellation of shares – (162) – (162) At 31 December 2021 3,782,428 (17,815) 315,549 4,080,162 Profit and total comprehensive income for the year – – 1,426,050 1,426,050 Dividends recognised as distribution (Note 15) – – (272,636) (272,636) Repurchase and cancellation of shares (59,946) 18,062 – (41,884) Transaction costs attributable to repurchase and cancellation of shares – (247) – (247) At 31 December 2022 3,722,482 – 1,468,963 5,191,445